Volume 27, Number 3—March 2021
Dispatch
Antibody Responses 8 Months after Asymptomatic or Mild SARS-CoV-2 Infection
Pyoeng Gyun Choe1, Kye-Hyung Kim1, Chang Kyung Kang, Hyeon Jeong Suh, EunKyo Kang, Sun Young Lee, Nam Joong Kim, Jongyoun Yi
, Wan Beom Park , and Myoung-don Oh
, Wan Beom Park , and Myoung-don Oh
Table 2
Positivity of antibodies to severe acute respiratory syndrome coronavirus 2 in 58 asymptomatic or mildly symptomatic patients at 8 mo after infection, South Korea*
| Characteristic | Anti-N pan-Ig ECLIA, no. (%)† | Anti-N IgG ELISA, no. (%)‡ | Anti-S IgG ELISA, no. (%)§ | Anti-S1 IgG ELISA, no. (%)¶ | sVNT, no. (%)# |
|---|---|---|---|---|---|
| Total |
53/58 (91.4) |
15/58 (25.9) |
50/58 (86.2) |
40/58 (69.0) |
31/58 (53.4) |
| Sex | |||||
| M | 21/23 (91.3) | 1/23 (4.3) | 17/23 (73.9) | 11/23 (47.8) | 7/23 (30.4) |
| F |
32/35 (91.4) |
14/35 (40.0)** |
33/35 (94.3)†† |
29/35 (82.9)** |
24/35 (68.6)** |
| Age, y | |||||
| <30 | 35/38 (92.1) | 5/38 (13.2) | 33/38 (86.8) | 25/38 (65.8) | 19/38 (50.0) |
| >30 |
18/20 (90.0) |
10/20 (50.0)** |
17/20 (85.0) |
15/20 (75.0) |
12/20 (60.0) |
| Duration of PCR positivity | |||||
| <14 d | 3/6 (50.0) | 3/6 (50.0) | 4/6 (66.7) | 3/6 (50.0) | 2/6 (33.3) |
| >14 d |
48/50 (96.0)** |
10/50 (20.0) |
44/50 (88.0) |
36/50 (72.0) |
27/50 (54.0) |
| Disease severity | |||||
| Asymptomatic | 7/7 (100) | 0/7 (0) | 5/7 (71.4) | 4/7 (57.1) | 4/7 (57.1) |
| Mildly symptomatic | 46/51 (90.2) | 15/51 (29.4) | 45/51 (88.2) | 36/51 (70.6) | 27/51 (52.9) |
*Anti-N, antinucleocapsid; anti-S, antispike; anti-S1, antispike subunit; ECLIA, electrochemiluminescence immunoassay; pan-Ig, panimmunoglobulin; sVNT, surrogate virus neutralization test. †Roche Diagnostics (https://diagnostics.roche.com). ‡Epitope Diagnostics (https://www.epitopediagnostics.com). §InBios International (https://www.inbios.com). ¶Euroimmun (https://www.euroimmune.com). #GenScript (https://www.genscript.com). **p<0.01. ††p<0.05.
1These first authors equally contributed to this article.
Page created: December 22, 2020
Page updated: February 21, 2021
Page reviewed: February 21, 2021
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.